Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Collegium Pharmaceutical Inc. (COLL:NASDAQ), powered by AI.
Collegium Pharmaceutical Inc. is currently trading at $34.64. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Collegium Pharmaceutical Inc. on Alpha Lenz.
Collegium Pharmaceutical Inc.'s P/E ratio is 17.5.
“Collegium Pharmaceutical Inc. trades at a P/E of 17.5 (fair value) with strong ROE of 23.7%. 3Y revenue CAGR of 18.9% highlights clear growth momentum.”
Ask for details →Collegium Pharmaceutical Inc. is a biotechnology company specializing in the development and commercialization of innovative medications aimed at addressing under-treated medical conditions in pain management. The company places significant emphasis on creating abuse-deterrent formulations of opioid and non-opioid medications, which are crucial in the context of the ongoing opioid crisis. Collegium Pharmaceutical’s products such as Xtampza ER, an extended-release oral formulation used for managing chronic pain, highlight its commitment to safer medication options. Operating primarily within the healthcare sector, the company collaborates with medical professionals and institutions to promote best practices in pain medication prescription and use. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical plays a vital role in the pharmaceutical industry by advancing treatment options that prioritize patient safety and therapeutic efficiency. Through its focus on responsible medication use and innovation, the company seeks to contribute to public health solutions that combat the challenges associated with pain management.
“Collegium Pharmaceutical Inc. trades at a P/E of 17.5 (fair value) with strong ROE of 23.7%. 3Y revenue CAGR of 18.9% highlights clear growth momentum.”
Ask for details →Collegium Pharmaceutical Inc. (ticker: COLL) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 357 employees. Market cap is $1.1B.
The current price is $34.64 with a P/E ratio of 17.47x and P/B of 3.64x.
ROE is 23.70% and operating margin is 22.86%. Annual revenue is $781M.